Efficacy and safety of OBI‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: Acquired haemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against human factor VIII (hFVIII). OBI‐1 is an investigational, B‐domain deleted, recombinant FVIII, porcine sequence, with low cross‐reactivity to anti‐hFVIII antibodies. Efficacy can be monitored with FVIII activity levels in addition to clinical assessments. This prospective, open label, phase 2/3 study was designed to evaluate the efficacy of OBI‐1 treatment for bleeding episodes in subjects with AHA. After an initial dose of 200 U kg−1, OBI‐1 was titrated to maintain target FVIII activity levels, in correlation with clinical assessments, throughout the treatment phase. All 28 subjects with AHA had a positive response to OBI‐1 treatment 24 h after initiation despite inhibition of FVIII activity levels immediately after infusion in 10 subjects with baseline anti‐porcine FVIII inhibitors. Control of the qualifying bleed was ultimately achieved in 24 of 28 subjects. No related serious adverse events, thrombotic events, allergic reactions or thrombocytopaenia occurred. The results of this study indicate that OBI‐1 is safe and effective in treating bleeding episodes in subjects with AHA. The ability to safely and effectively titrate dosing based on FVIII activity levels in this study demonstrates that OBI‐1 fulfils the unmet medical need to monitor the key coagulation parameter in AHA patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO
W Collins, P., Chalmers, E., Hart, D., Jennings, I., Liesner, R., Rangarajan, S., Talks, K., Williams, M., & R. M. Hay, C. (2013) · British Journal of Haematology · doi:10.1111/bjh.12463 · Cited by 159
Cited by
International Recommendations on the Diagnosis and Treatment of Acquired Hemophilia A
Tiede, A., Collins, P., Knoebl, P., Teitel, J., Kessler, C., Shima, M., Di Minno, G., d’Oiron, R., Salaj, P., Jiménez-Yuste, V., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.230771 · Cited by 401
Acquired hemophilia A: Updated review of evidence and treatment guidance
Kruse‐Jarres, R., Kempton, C. L., Baudo, F., Collins, P. W., Knoebl, P., Leissinger, C. A., Tiede, A., & Kessler, C. M. (2017) · American Journal of Hematology · doi:10.1002/ajh.24777 · Cited by 393
Self-citation(2022) · Blood transfusion · doi:10.2450/2022.0238-21 · Cited by 22
“In the pre-registration study, susoctocog alfa was successful in controlling bleeding episodes in 86% of 28 AHA patients with a median age of 70 years, being more effective when used as first-line therapy 55 .”
Influential
Metadata
- Authors
- Kruse‐Jarres, R., St‐Louis, J., Greist, A., Shapiro, A., Smith, H., Chowdary, P., Drebes, A., Gomperts, E., Bourgeois, C., Mo, M., Novack, A., Farin, H., & Ewenstein, B.
- Venue
- Haemophilia
- Publisher
- Wiley
- Published
- 2015-01-27
- Volume
- 21
- Issue
- 2
- Pages
- 162-170
- ISSN
- 1351-8216 (ISSN-L)
- 1365-2516
- OpenAlex
- W2087435777
- Cited by
- 176
- References
- 1
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.